针对B7-H3的临床试验纳入儿童高级别中枢神经系统肿瘤是否需要B7-H3免疫组化检测
该研究回顾性分析136例儿童高级别中枢神经系统肿瘤的CD276 mRNA和B7-H3蛋白表达,发现B7-H3表达在肿瘤类型间及类型内均存在显著差异,30%的弥漫性中线胶质瘤H3K27变异型和幕下室管膜瘤A型无或极低表达,且与患者年龄、肿瘤位置、表观遗传亚类或分子驱动因素无关,作者建议在B7-H3靶向治疗试验入组时获取肿瘤组织以评估B7-H3免疫组化表达作为生物标志物的价值。
要点
- B7-H3在儿童高级别中枢神经系统肿瘤中表达异质性大,30%的弥漫性中线胶质瘤H3K27变异型和幕下室管膜瘤A型无或极低表达。
- B7-H3表达差异与患者年龄、肿瘤位置、表观遗传亚类或分子驱动因素无关。
- 作者建议在B7-H3靶向治疗试验入组时获取肿瘤组织,以评估免疫组化B7-H3表达作为生物标志物的价值。
核心结论
- 该研究在迄今最大样本的儿童高级别中枢神经系统肿瘤集中发现B7-H3表达存在显著的患者间异质性和众多阴性病例,作者建议在B7-H3靶向治疗试验入组时获取肿瘤组织以评估免疫组化B7-H3表达作为生物标志物的价值。
研究设计与样本
- 回顾性分析来自Princess Máxima儿童肿瘤中心的136例儿童高级别中枢神经系统肿瘤,包括胚胎性肿瘤44例、高级别神经上皮肿瘤4例、室管膜瘤30例、高级别胶质瘤58例,检测CD276 mRNA和B7-H3免疫组化蛋白表达并与临床分子数据关联。
主要发现
- B7-H3 mRNA和蛋白表达在肿瘤类型间及类型内均存在显著差异。
- 30%的弥漫性中线胶质瘤H3K27变异型和幕下室管膜瘤A型无或极低表达B7-H3。
- B7-H3表达差异与患者年龄、肿瘤位置、表观遗传亚类或分子肿瘤驱动因素无关。
- B7-H3阴性病例中肿瘤细胞比例高,排除了低肿瘤细胞比例导致阴性染色的可能。
关键数值与推荐
- 136例儿童高级别中枢神经系统肿瘤中,胚胎性肿瘤n=44、高级别神经上皮肿瘤n=4、室管膜瘤n=30、高级别胶质瘤n=58。
- 30%的弥漫性中线胶质瘤H3K27变异型和幕下室管膜瘤A型显示无或极低B7-H3表达。
临床怎么用
- 作者建议在B7-H3靶向治疗试验(包括CAR-T细胞)入组时获取肿瘤组织,以评估免疫组化B7-H3表达作为生物标志物的价值,并最终实现更个体化的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric high-grade central nervous system (pHG-CNS) tumors are the leading cause of childhood cancer-related deaths, partly due to poor response to standard treatments. B7-H3 is reportedly expressed in pHG-CNS tumors, making antigen-targeting therapies, including anti-B7-H3 chimeric antigen receptor T-cell (CAR-T) therapy, promising. However, given substantial inter-tumoral protein expression diversity in CNS tumors, it's unclear which patients might benefit from these treatments. Therefore, we studied B7-H3 expression in a large set of pHG-CNS tumors. METHODS: We retrospectively analyzed 136 pHG-CNS tumors (embryonal tumors (n = 44), high-grade neuroepithelial tumors (n = 4), ependymomas (n = 30),high-grade gliomas (HGGs, n = 58)) from the Princess Máxima Center for Pediatric Oncology. CD276 mRNA (encoding B7-H3) and immunohistochemical (IHC) protein expression of B7-H3 was measured and correlated to clinical-molecular data. RESULTS: Large variability of B7-H3 mRNA and protein expression was observed both between and within tumor types. Many tumors expressed B7-H3, but 30% of diffuse midline glioma H3K27-altered and ependymomas posterior fossa type A showed no or minimal expression. This variability was unrelated to patient age, tumor location, epigenetic subclass, or molecular tumor driver. B7-H3 negative cases were high in tumor cells, ruling out low tumor cell percentage as an explanation for negative staining. CONCLUSIONS: Our study of B7-H3-expression in the largest pHG-CNS tumor set to date revealed significant interpatient variability and numerous negative cases. Our results urge for tumor tissue acquisition at enrollment in B7-H3 targeting therapeutic trials (including CAR-T cells) in order to thoroughly assess the value of IHC B7-H3 expression as biomarker and, ultimately, to allow for more tailored therapy.
引用
- Kranendonk MEG, Hoogendijk R, Lammers JAS, et al. Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3? Neuro Oncol. 2025. PMID: 40207575. doi:10.1093/neuonc/noaf095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。